While the inherent nature of trading in the biotech/healthcare sector is always risky and there are far more stories of failure than success as many drugs fail to make it through late stage trials, proper DD and investigation into developments at Synergy Pharmaceuticals (SGYP) could reveal an attractive buying opportunity for those willing to play the volatile nature of the sector.

Synergy shares have slipped over the past couple of weeks and are again trading at levels under the four dollar mark, prices not seen in many months beforehand. With key catalysts pending later in the year and with a product in the late stages of development that could be worth billions over the long run on the open market, SGYP could be trading for quite the relative bargain at the current time. As the year progresses and the significant trial catalyst draws nearer, Synergy could be gearing up for a reversal from the current downtrend.

READ FULL ARTICLE HERE...